drugset / Trial / NCT01606228

A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

NCT01606228

Phase 3 Completed 188 enrolled Janssen Pharmaceutica
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the tolerability, safety and efficacy of flexibly dosed paliperidone extended release (ER) among patients with schizophrenia.

Timeline

Start
2007-12
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Paliperidone Unknown 3 mg Oral
Subject Paliperidone Unknown 12 mg Oral

Indications